Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined With Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis

NCT03809663 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03809663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03809663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined With Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
March 15, 2019
Completion date
December 22, 2020
Enrollment
251 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis